Role of Positron Emission Tomography in the Management of Head and Neck Cancer in the Molecular Therapy Era
Overview
Authors
Affiliations
Purpose Of Review: The utility of positron emission tomography-computed tomography has increasingly been studied during the last years. Positron emission tomography-computed tomography offers a holistic approach of cancer diagnosis as it can integrate structural, functional, metabolic, and molecular information of tumour. The technique offers three-dimensional, high-resolution, whole body, and quantitative imaging. 18F-Fluoro-2-deoxy-D-glucose still remains the only tracer widely available. Other tracers have been designed for assessment of proliferation, amino acid uptake, and hypoxia.
Recent Findings: 18F-Fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography seems the most appropriate technique for the assessment of locoregional lymph node involvement in head and neck cancer. False negativity of positron emission tomography-computed tomography in case of micrometastatic lymph node disease should be compensated by the implementation of the sentinel node scintigraphy guided biopsy. 18F-Fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography has a very high sensitivity and negative predictive value in detecting residual disease after radiotherapy or early recurrent disease. Radiotherapy planning can use the 18F-fluoro-2-deoxy-D-glucose uptake distribution for increasing the accuracy of delineation of the target volumes in conformal radiotherapy. Positron emission tomography-computed tomography with other tracers such as deoxy-18F-fluorothymidine for proliferation mapping and [F-18] fluoromisonidazole for hypoxia mapping are currently being studied.
Summary: Major studies have now confirmed the utility of positron emission tomography-computed tomography in the different phases of diagnostic and therapeutic phases of the management of patients with head and neck cancer.
Rajendran J, Krohn K Semin Nucl Med. 2015; 45(2):151-62.
PMID: 25704387 PMC: 4339212. DOI: 10.1053/j.semnuclmed.2014.10.006.
Mason N, Lopresti B, Ruszkiewicz J, Dong X, Joyce S, Leef G Am J Nucl Med Mol Imaging. 2013; 3(1):16-31.
PMID: 23342298 PMC: 3545366.
Viable tumor in postchemoradiation neck dissection specimens as an indicator of poor outcome.
Ganly I, Bocker J, Carlson D, DArpa S, Coleman M, Lee N Head Neck. 2011; 33(10):1387-93.
PMID: 21928410 PMC: 3772770. DOI: 10.1002/hed.21612.